• Manije Kahbazi
  • Hamidreza Rezapour
  • Farshad Jafari
  • Mohammad Arjomandzadegan
  • Masume Sofian
  • Nader Zarinfar
  • Hossein Sarmadiayan
  • Amir Reza Najmi


Introduction: Iran is one of the endemic regions with high prevalence of brucellosis. Severalserological markers for diagnosis and response to treatment are available. Serum level of SolubleInterleukin-2 Receptor alpha (SIL-2R) is a new marker to assess response to therapy and clinicalrelapse of brucellosis. This study intends to investigate the serum levels of SIL-2R before andafter treatment, to evaluate this marker for patients responding to treatment of brucellosis.Methods: This study is an analytical cross-sectional study. Forty patients who had clinical signs ofbrucellosis and serological tests confirmed the disease have been treated with standard antibioticsfor 6 weeks. 2ME and SIL-2R levels were measured before and after treatment and these valueswere compared. Results: Among the 40 patients, 27 patients (67.5%) had improvement insymptoms and 13 patients (32.5%) had no symptoms after treatment. In Comparing serum levels ofSIL-2R and 2ME before and after treatment, decreasing of both markers after treatment wassignificant (p<0.001). In patients with false positive for 2ME, SIL-2R in 57% of patients had areduction, but in patients with false negative for 2ME, SIL-2R in only 28% of patients increased.Conclusion: Not only is Serum level of SIL-2R useful for predicting response to treatment ofbrucellosis, but also in cases of false positive of 2ME can be helpful.Keywords: Brucellosis, SIL-2R, 2ME


Longo DL, Fauci AS, Kasper DL. Harrison’s Principles of

Internal Medicine, McGraw-Hill Professional; 18th ed., 2011.

Galanakis E, Bourantas KL, Leveidiotou S, Lapatsanis PD.

Childhood brucellosis in north – western Greece : a retrospective

analysis. Eur J Pediatr 1996;155:1–6.

Hadadi A, Rasoulinezhad Mehrnaz, Afhami Sh, Mohraz M.

Epidemiological, Clinical, Para clinical Aspects of Brucellosis in

Imam Khomeini and Sina Hospital of Tehran (1998–2005). J

Kermanshah Univ Med Sci, Iran 2006;10(3):242.

Baldwin CL, Winter AJ. Macrophages and Brucella. Immunol

Ser 1994;60:363–80 .

Shapoury R, Imani Fooladi AA, Rahnama M, Izadi M.

Designing and validation of indirect and competitive ELISA for

diagnosis of Brucellosis in human. J Military Med.


Zaitseva MB, Golding H, Betts M. Human peripheral blood

CD4C and CD8CT-cells express Th1-like cytokine mRNA and

proteins following in vitro stimulation with heat-activated

Brucella abortus. Infect Immun 1995;63:2720–8 .

Zhan Y, Liu Z, Cheers C. Tumor necrosis factor alpha and

interleukin-12 contribute to resistance to the intracellular

bacterium Brucella abortus by different mechanisms. Infect

Immun 1996;64:2782–6.

Kamal Esalatmanesh, Zahra Soleimani, Abbas Arj, Hossein

Akbari, Mansour Salesi. Diagnostic value of ELISA (IgG and

IgM) test in brucellosis patients in Kashan during 2004. Feyz


Agranovich I, Scott DE, Terle D, Lee K, Golding B. Down

regulation of Th2 responses by Brucella abortus, a strong Th1

stimulus, correlates with alterations in the B7.2-CD28 pathway.

Infect Immun 1999;67:4418–26.

Saleh P. Diagnostic value of brucella (IgM and IgG) in patients

with brucellosis in Kashan. Infect Dis 1999;44:59–63. [Article in


Alexandros C. Makis, Emmanouil Galanakis, Eleftheria C.

Hatzimichael, Zoe L. Papadopoulou, Antigone. Serum level of

soluble interleukin-2 receptor alpha (SIL-2Rα) as a predictor of

outcome in brucellosis J Infect 2005;51:206–10.

Skendros P. Diminished Percentage of CD4+ T-lymphocytes

expressing interleukine-2receptor alpha in chronic brucellosis. J

Infect 2007;54(2):192–7.

Honda M, Kitamura K, Takeshita T, Sugamura K, Tokunaga T.

Identification of a soluble IL-2 receptor beta-chain from human

lymphoid cell line cells. J Immunol 1990;145:4131–5.

Galanakis E, Makis A, Bourantas KL, Papadopoulou ZL.

Interleukin-3 and interleukin-4 in childhood brucellosis. Infection